Novel drugs are new drugs that, prior to approval, have never been marketed in the U.S.
|
Drug Name |
Active Ingredient |
Approval Date |
FDA-approved Use |
|
Ziihera |
zanidatamab-hrii |
11/20/2024 |
To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer |
|
Revuforj |
revumenib |
11/15/2024 |
To treat relapsed or refractory acute leukemia |
|
Vyloy |
zolbetuximab-clzb |
10/18/2024 |
To treat gastric or gastroesophageal junction adenocarcinoma |
|
Itovebi |
inavolisib |
10/10/2024 |
To treat locally advanced or metastatic breast cancer |
|
Lazcluze |
lazertinib |
8/19/2024 |
To treat non-small cell lung cancer |
|
Voranigo |
vorasidenib |
8/6/2024 |
To treat Grade 2 astrocytoma or oligodendroglioma |
|
Imdelltra |
tarlatamab-dlle |
5/16/2024 |
To treat extensive stage small cell lung cancer |
|
Ojemda |
tovorafenib |
4/23/2024 |
To treat relapsed or refractory pediatric low-grade glioma |
|
Anktiva |
nogapendekin alfa inbakicept-pmln |
4/22/2024 |
To treat bladder cancer |
|
Lumisight |
pegulicianine |
4/17/2024 |
To use as an optical imaging agent for the detection of cancerous tissue |
|
Tevimbra |
tislelizumab-jsgr |
3/13/2024 |
To treat unresectable or metastatic esophageal squamous cell carcinoma |
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
